ATE408340T1 - Prävention und behandlung von mycoplasma- assoziierten krankheiten mit trans-sialidase und/oder neuraminidase - Google Patents

Prävention und behandlung von mycoplasma- assoziierten krankheiten mit trans-sialidase und/oder neuraminidase

Info

Publication number
ATE408340T1
ATE408340T1 AT01944764T AT01944764T ATE408340T1 AT E408340 T1 ATE408340 T1 AT E408340T1 AT 01944764 T AT01944764 T AT 01944764T AT 01944764 T AT01944764 T AT 01944764T AT E408340 T1 ATE408340 T1 AT E408340T1
Authority
AT
Austria
Prior art keywords
mycoplasma
prevention
treatment
sialidase
neuraminidase
Prior art date
Application number
AT01944764T
Other languages
English (en)
Inventor
Maria De Lourdes Higuchi
Sergio Schenkman
Original Assignee
Maria De Lourdes Higuchi
Sergio Schenkman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR0002989-0A external-priority patent/BR0002989A/pt
Application filed by Maria De Lourdes Higuchi, Sergio Schenkman filed Critical Maria De Lourdes Higuchi
Priority claimed from BR0102648A external-priority patent/BRPI0102648B8/pt
Application granted granted Critical
Publication of ATE408340T1 publication Critical patent/ATE408340T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01944764T 2000-07-03 2001-07-03 Prävention und behandlung von mycoplasma- assoziierten krankheiten mit trans-sialidase und/oder neuraminidase ATE408340T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR0002989-0A BR0002989A (pt) 2000-07-03 2000-07-03 Medicamento anti-micoplasma e suas associacões com outros agentes infecciosos
BR0102648A BRPI0102648B8 (pt) 2001-07-03 2001-07-03 uso de uma composição que impeça ou iniba uma infecção por micoplasma

Publications (1)

Publication Number Publication Date
ATE408340T1 true ATE408340T1 (de) 2008-10-15

Family

ID=25663407

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01944764T ATE408340T1 (de) 2000-07-03 2001-07-03 Prävention und behandlung von mycoplasma- assoziierten krankheiten mit trans-sialidase und/oder neuraminidase

Country Status (5)

Country Link
US (1) US7108851B2 (de)
EP (1) EP1296554B1 (de)
AT (1) ATE408340T1 (de)
CA (1) CA2383850C (de)
DE (1) DE60135843D1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
US8822232B2 (en) 2003-03-28 2014-09-02 Maria De Lourdes Higuchi Diagnosis, prevention and treatment of disorders characterized by undesirable cell proliferation
US7732410B2 (en) * 2003-03-28 2010-06-08 Higuchi Maria De Lourdes Compositions for inhibiting atherosclerosis
BRPI1004987A2 (pt) 2010-11-26 2013-03-26 Maria De Lourdes Higuchi prevenÇço e tratamento de doenÇas associadas as micoplasma
US20140178891A1 (en) * 2003-03-28 2014-06-26 Maria De Lourdes Higuchi Diagnosis, Prevention and Treatment of Disorders Characterized by Undesirable Cell Proliferation
US7674832B2 (en) * 2003-03-28 2010-03-09 Higuchi Maria De Lourdes Compositions for promoting wound healing and treating psoriasis
US10328128B2 (en) * 2014-09-17 2019-06-25 Ansun Biopharma, Inc. Treatment of infection by human enterovirus D68

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9621771D0 (en) 1996-10-18 1996-12-11 St George S Enterprises Ltd Method of treatment of heart disease

Also Published As

Publication number Publication date
EP1296554B1 (de) 2008-09-17
EP1296554A4 (de) 2005-03-09
DE60135843D1 (de) 2008-10-30
CA2383850A1 (en) 2002-01-10
US7108851B2 (en) 2006-09-19
CA2383850C (en) 2012-02-07
US20030124109A1 (en) 2003-07-03
EP1296554A2 (de) 2003-04-02

Similar Documents

Publication Publication Date Title
DE60040487D1 (de) Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität
ATE477816T1 (de) Botulinum toxin zur behandlung von akuten verletzungen der skelettmuskeln
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
BR0110975A (pt) Tratamento profilático e terapêutico de doenças infecciosas ou outras doenças com compostos à base de mono- e disacarìdeos
DE69534130D1 (de) Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen.
EA200500487A1 (ru) Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
ATE544466T1 (de) Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BRPI0516209A (pt) prevenção e tratamento de doenças associadas a micoplasmas
ATE408340T1 (de) Prävention und behandlung von mycoplasma- assoziierten krankheiten mit trans-sialidase und/oder neuraminidase
TR200402670T4 (tr) Obezitenin tedavisi ve/veya profilaksına uygun bileşiklerin bulunması için yöntem
PT1140113E (pt) Utilizacao de bisfosfonatos para profilaxia e tratamento de processos infecciosos
BR0209145A (pt) Vacina contra varìola
WO2002002050A3 (en) Prevention and treatment of mycoplasma-associated diseases
ATE375152T1 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
TR200101980T2 (tr) Arilalkanoil türevleri, bunların preparasyon işlemleri
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
ATE237616T1 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv
DE69803303T2 (de) Verwendung von endipalen zur behandlung von schuppenflechte
ATE214923T1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee